Dr Matthew Anderson and Dr Fabienne Lucas (both members of the College of American Pathologists’ Allogeneic Cell Therapy Project Team) explore the role of surrogate biomarkers in assessing the persistence and efficacy of allogeneic cell therapies (ACTs), highlighting the challenges in developing reliable, standardized biomarkers.
For the full article click here: How can diagnostic laboratories accelerate the clinical adoption of allogeneic cell therapies?